Hims & Hers Drops Nearly 10% on the Day Its Lilly Deal Landed

As seen on the 24/7 Wall St. homepage on November 9, 2026.

HIMS Hims & Hers
Regular session
$23.41
-9.98% off the open $26.00
$25$24$23

Hims & Hers gave back nearly 10% from a $26 open on the day its Eli Lilly deal press release landed. Eli Lilly is up 3.08%, with the partnership not translating into credit for the telehealth side.

Before the move last 24 hours
  1. Press release

    Hims & Hers Lilly deal press release

    PR Newswire
Related stocks today

Moves: Nov 9, 2:40 PM ET · Alpha Vantage quote

Continue ReadingShow less

Hims & Hers finished regular trading down nearly 10%, and the selloff came on the same day the company announced a partnership with Eli Lilly, news that would ordinarily support a telehealth stock.

Eli Lilly rose 3.08% on the day, a split that suggests investors see the arrangement as more favorable to the pharmaceutical giant than to the telehealth platform.

Sponsored

The stock held in the mid-$24 range early before a pronounced leg lower, and it found no sustained recovery through the afternoon.

The Lilly press release landed during the trading day, giving the market a full session to price it in, and shares ended near their lows rather than paring the decline.

Sources

Mentioned: HIMS, LLY

Related Market Updates

HIMS Hims & Hers
Q3 2026
EPS
-$0.14
est $0.06 -348.7%
Revenue
$890M
est $893M -0.3%

Gross margin collapsed to 57% from 74% a year ago, turning 49% revenue growth into a loss where analysts modeled a profit. Management also trimmed full-year adjusted EBITDA guidance to $257 million to $277 million, so the international land grab is costing more than the top line implies.

Read more
HIMS Hims & Hers
Regular session
$22.79
-12.35% off the open $26.00
$25$24$23

Hims & Hers is down 12.35% to $22.79 after announcing its expanded-access deal with Eli Lilly, with partner Eli Lilly up 3.36%. Traders are pricing the agreement as a margin concession rather than a volume win.

Before the move last 24 hours
  1. Press release

    Hims & Hers Lilly deal press release

    PR Newswire
Related stocks today

Moves: Nov 9, 3:40 PM ET · Alpha Vantage quote

Read more
HIMS Hims & Hers
Regular session
$23.12
-11.92% open $26.25
$26$25$23

Nearly 12% off the $26.25 open to $23.12 takes roughly $600 million off a $5.2 billion company in one session. Double-digit intraday swings are routine in this name, which is exactly why the close matters more than the dip.

Read more
Jim Cramer
PODCAST Mad Money w/ Jim Cramer Jim Cramer · 44 min

Mad Money w/ Jim Cramer 11/3/26

  • Cramer calls the mega caps millstones: Nasdaq rose 0.83% while the Dow fell 197 points
  • Strong after-hours results from AMD and Arista Networks as proof non-Magnificent-Seven tech can lead
  • Oracle's $10 billion block priced at $116 and traded to $126, a sign buyers see a floor in tech
  • Wants a crescendo washout before committing more; Apple's reaction and a Palantir selloff weighed

The leadership baton is being passed to second-tier data center names, and Cramer would rather own companies with clean balance sheets than the big caps issuing debt and equity to stay in the AI race. He is not calling a bottom yet: without a high-volume reversal day, he keeps money elsewhere.

Read more
Thierry Borgeat @thierryborgeat Quote post

Lilly is absorbing lower GLP-1 pricing, with 53% more patients on its drugs funding a push into gene editing and oncology.

Eli Lilly cut its prices 15% and still sold $24.4B in three months, up 39%. How? 53% more people are taking its drugs. Its next weight loss shot took off about 28% of patients' body weight in trials. The weight loss money is now paying for gene editing, cancer drugs and cell https://t.co/eaqcVLBSEm [Quoted @ThierryBorgeat]: CEO of Eli Lilly $LLY The biggest beneficiary of AI is Biotech. The case: https://t.co/V2nfeWzPeh https://t.co/iyKmslKzcv https://t.co/3gvq5zfzdP
  • Replies0
  • Reposts0
  • Likes0
Read more
52-week highs
51 stocks hit new 52-week highs this week
  • LNGCheniere Energy$330.32+11.7%
  • REGNRegeneron$927.89+8.9%
  • LLYEli Lilly$1,417.54+8.5%
  • GILDGilead Sciences$170.68+8.5%
  • RBRKRubrik$124.15+8.1%
  • COPConocoPhillips$154.03+5.1%
  • EOGEOG Resources$165.54+4.8%
  • XOMExxon Mobil$187.25+4.6%
  • EENI$60.8+4.3%
  • EMREmerson Electric$164.94+4.2%

51 stocks printed fresh 52-week highs this week, and the leadership is energy plus big biotech: Cheniere cleared its prior peak by 11.7%, with Regeneron, Eli Lilly and Gilead all stretching more than 8% past theirs.

Read more
Biggest movers · At the close
Gainers
  • FVRRFiverr International$9.03+11.7%
  • CAVACava$59.05+8.8%
  • LNGCheniere Energy$320.85+7.8%
  • LLYEli Lilly$1,374.21+6.7%
  • APPSDigital Turbine$10.56+6.5%
Losers
  • NOWServiceNow$110.3-26.5%
  • FTNTFortinet$137.93-20.8%
  • MRVLMarvell Technology$218.95-13.0%
  • GOOGLGoogle$283.7-12.7%
  • GOOGGoogle$282.03-12.4%

ServiceNow closed down 26.53%, the deepest drop across 382 priority names and more than a quarter of its value gone in one session.

Read more
LLY Eli Lilly
Regular session
$1385.95
+4.05% open $1331.99

A 4.05% intraday gain on a $1.2 trillion company is roughly $50 billion in market value, and it follows this morning's Q3 2026 earnings beat. Moves this size are rare for a megacap this heavy, so keep an eye on whether it holds into the close.

Read more
Biggest movers · On the open
Gainers
  • LLYEli Lilly$1,387.74+7.7%
  • FVRRFiverr International$8.62+6.6%
  • CAVACava$57.35+5.7%
  • MRKMerck &$148+5.0%
  • LNGCheniere Energy$312.37+4.9%
Losers
  • NOWServiceNow$113.7-24.3%
  • FTNTFortinet$131.87-24.3%
  • GOOGLGoogle$281.45-13.4%
  • GOOGGoogle$279.19-13.3%
  • MRVLMarvell Technology$219.79-12.7%

A 32-point gap separates the best and worst names in a 381-stock universe today: ServiceNow and Fortinet both shed roughly 24% while Eli Lilly leads the upside at 7.72%. Positioning set for a quiet session is already wrong.

Read more
LLY Eli Lilly
Q3 2026
EPS
$7.48
est $6.67 +12.2%
Revenue
$24.40B
est $22.62B +7.9%

Lilly lifted full-year revenue guidance to $91 billion to $92 billion, up from $85 billion to $87 billion, after tirzepatide volume rose 53% worldwide. EPS and revenue both beat expectations despite acquired IPR&D charges from the AtaiBeckley and Curevo deals landing in the quarter.

Read more
LLY Eli Lilly
New 52-week high $1,283.66 +0.3% vs prior high · 2026-08-19
$1.3k$1k$765

Eli Lilly just cleared its August 19 peak with a $1,283.66 close, a new 52-week high for the $1.1 trillion drugmaker. The stock has climbed roughly 60% from last October's $803 level, and two months of chop are now resolved to the upside.

Read more